FIELD: immunology.
SUBSTANCE: antibody to PD-L1 and an antigen-binding fragment are proposed, characterized by amino acid sequences of complementarity-determining regions (hereinafter – CDRs) with SEQ ID NO: 1-3, included in variable regions of a heavy chain, and with SEQ ID NO: 5-7, included in variable regions of a light chain, or with SEQ ID NO: 1, 2, 11, included in variable regions of the heavy chain, and with SEQ ID NO: 13, 6, 7, included in variable regions of the light chain. In addition, nucleic acid encoding the antibody or its antigen-binding fragment; an expression vector; a cell for the production of the antibody or its antigen-binding fragment; a method for the production of the antibody or its antigen-binding fragment; and a composition containing the antibody or its antigen-binding fragment as an active ingredient for prevention or treatment of cancer are proposed.
EFFECT: invention allows for obtainment of a new antibody or its antigen-binding fragment specifically binding to PD-L1, which are effective for prevention or treatment of cancer.
8 cl, 17 dwg, 9 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
